Comparing the cost-effectiveness of two alternative bypassing agents (aryoseven & feiba )for haemophilia
Phase 3
- Conditions
- Haemophilia.Hereditary factor VIII deficiency
- Registration Number
- IRCT2013020612380N1
- Lead Sponsor
- Aryogen biopharma co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
patients with severe hemophilia a with high inhibitor titers (greater than or equal to 5 Bethesda) in pilot studies to assess the attitude of coagulation shortcuts are classified.
Exclusion criteria: patients who have previously unclassified; patients with coagulation problems, developed liver problems; patients who received coagulation products is over 5 days ago and patients who have bleeding arthritis in the joint within 7 days ago.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: 1, 3, 6, 9 and 12 hours after intervention. Method of measurement: Measure kavakli.;Range of motion. Timepoint: 1, 3, 6, 9 and 12 hours after intervention. Method of measurement: Measure kavakli.
- Secondary Outcome Measures
Name Time Method Bleeding control. Timepoint: 24 hours. Method of measurement: Evaluation of treatment success.